NYSE$ELAN

Elanco Animal Health Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Elanco's financial performance in Q1 2024 was marked by revenue of $1,205 million and adjusted EPS of $0.34, despite challenges from the ERP Blackout.

Elanco Animal Health reported first quarter 2024 financial results, with revenue of $1,205 million and a reported EPS of $0.06. The company's performance was impacted by a shift in customer purchasing related to the ERP Blackout in 2023. Elanco is updating its full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates.

  • Revenue reached $1,205 million.
  • Reported net income was $32 million, with an adjusted net income of $167 million.
  • Adjusted EBITDA stood at $294 million, representing 24.4% of revenue.
  • Reported EPS was $0.06, while adjusted EPS was $0.34.

Headline financials

Total Revenue

$1.21B

Previous: $1.26B-4.1%
EPS

$0.06

Previous: $0.45-86.7%
Adjusted EBITDA

$294M

No prior period
Adjusted EBITDA Margin

24.4%

No prior period
Capital Expenditures

-$24M

Previous: -$20M-20.0%
Free Cash Flow

$8M

Previous: $83M-90.4%
Net Income

$32M

Previous: $103M-68.9%
Operating Income

-$1.12B

Previous: -$1.12B-0.3%
Gross Profit

$690M

Previous: $763M-9.6%
Cash & Equivalents

$345M

Previous: $318M+8.5%
Total Assets

$14B

Previous: $15.8B-11.1%
R&D Expense

$87M

No prior period
Stock-Based Comp

$11M

Previous: $12M-8.3%

Revenue & EPS history

Elanco · Revenue · Quarterly

$1.21B

Q1 2024-4.1%vs Q1 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Elanco · $1.58B total across 5 segments · Q3 2023

  • Farm Animal
    $561M
  • Pet Health
    $495M+5.1%
  • Cattle
    $242M+3.9%
  • Poultry
    $184M+15.7%
  • Swine
    $93M+10.7%

Forward guidance

Elanco is updating financial guidance for the full year 2024 and providing guidance for the second quarter of 2024. The company now anticipates revenue between $4,460 and $4,515 million and adjusted EPS of $0.88 to $0.96 for the full year. For the second quarter of 2024, the company anticipates revenue between $1,145 and $1,170 million and adjusted EPS between $0.23 and $0.26.

Tailwinds

  • Improved operational performance
  • Lower interest expense
  • Lower tax rate
  • Strength in U.S. farm animal business
  • Strength in International pet health business

Headwinds

  • Unfavorable impact of foreign exchange rates
  • Reduced sales of Kexxtone due to manufacturing process review
  • Headwind from unfavorable impact of foreign exchange rates in Q2
  • ERP system go-live in April 2023 impacted sales order processing
  • Shift of revenue from Q2 2023 to Q1 2023 due to ERP Blackout

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+2.0%

Avg return

Earnings day

+2.8%

Avg return

5 days after

+1.1%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+27.2%

Q1 2024

Best reaction

-16.3%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+13.9%-5.6%+2.6%
Q4 2025+7.3%+6.7%-0.7%
Q3 2025-4.2%-1.0%-2.7%
Q1 2025+26.2%+34.8%+46.2%
Q4 2024-3.7%+0.5%-2.7%
Q3 2024+9.4%+9.8%-2.8%
Q2 2024+5.3%+12.6%+21.9%
Q1 2024+27.2%+25.7%+34.7%
Q4 2023+0.5%-2.1%-1.2%
Q3 2023+15.9%+14.1%+36.4%
Q2 2023+7.0%+4.5%+2.7%
Q1 2023-3.8%-8.4%-0.1%
Q4 2022-6.9%-11.0%-33.1%
Q3 2022-10.3%+0.4%-6.7%
Q2 2022-1.6%+3.3%-23.9%
Q1 2022-7.9%-6.4%+1.5%
Q4 2021+8.2%+12.4%+3.3%
Q3 2021+1.2%+0.3%-14.3%
Q2 2021-16.3%-12.3%-4.2%
Q1 2021+3.8%+3.4%+10.1%
Q4 2020+2.8%+9.0%-9.8%
Q3 2020-4.7%-8.0%-9.8%
Q2 2020+11.7%+17.3%+37.7%
Q1 2020-13.5%-12.9%+3.6%
Q4 2019-0.7%-1.4%-42.5%
Q3 2019-1.9%-3.1%-1.2%
Q2 2018-4.8%-1.3%-4.6%
Q2 2019-4.8%-1.3%-4.6%
Q1 2019+6.1%+3.9%+4.1%
Q4 2018-2.4%-1.7%-2.7%
Q3 2018+3.7%+3.7%-1.9%
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro